Characterization of hepatic pathology during azoxymethane-induced acute liver failure

Figure 4 Measures of hepatic inflammation are increased in azoxymethane-treated mice. A: Immunohistochemistry images for CD16 in livers from vehicle- and azoxymethane (AOM)-treated mice at pre, minor, major and coma time points; B and C: Relative CCL2 mRNA and protein expressed in pg of CCL2 per mg of protein in liver homogenates from mice treated with vehicle or AOM at pre, minor, major and coma time points; D and E: Tumor necrosis factor α (TNFα) mRNA and protein reported as pg of TNFα per mg of protein from liver homogenates of vehicle or AOM-treated mice at indicated time points. n ≥ 3 for each group for all analyses. ^aP < 0.05 compared to vehicle-treated mice.